SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Study

Phase 3positivePositive

AI Analysis

Summary

Akeso achieved a positive outcome in a Phase III clinical trial for biliary tract cancer, contributing to SMMT's stock rise. Specific efficacy details and drug name are not provided in the article.

Clinical Trial Data

Phase

III

Primary Endpoint

Met

Importance:7/10

Sentiment:

0.70

Phase 3Biliary Tract CancerClinical TrialPositive Data

Related Companies

$AZN

Read the original article

Published by yahoo_finance on August 27, 2026 4:11 PM

Read Original